Mineralys Therapeutics (MLYS) Non-Current Assets (2022 - 2026)

Quarterly results put Non-Current Assets at $392000.0 for Q1 2026, down 9.89% from a year ago — trailing twelve months through Mar 2026 was $1.4 million (down 29.06% YoY), and the annual figure for FY2025 was $420000.0, down 23.91%.

Mineralys Therapeutics has reported Non-Current Assets over the past 5 years, most recently at $392000.0 for Q1 2026.

  • Non-Current Assets reached $392000.0 in Q1 2026 per MLYS's latest filing, down from $420000.0 in the prior quarter.
  • Across five years, Non-Current Assets topped out at $31.2 million in Q1 2023 and bottomed at $151000.0 in Q3 2025.
  • Median Non-Current Assets over the past 5 years was $506000.0 (2024), compared with a mean of $5.2 million.
  • The largest annual shift saw Non-Current Assets surged 55.3% in 2023 before it tumbled 98.62% in 2024.
  • Over 5 years, Non-Current Assets stood at $1.6 million in 2022, then skyrocketed by 55.3% to $2.5 million in 2023, then crashed by 78.21% to $552000.0 in 2024, then dropped by 23.91% to $420000.0 in 2025, then dropped by 6.67% to $392000.0 in 2026.
  • Business Quant data shows Non-Current Assets for MLYS at $392000.0 in Q1 2026, $420000.0 in Q4 2025, and $151000.0 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Assets (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn - 4.56 Mn
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn - 62,953.78
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn 486.60 Mn
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn - 5.83 Mn
5 Akari Therapeutics 605.66 Bn 605.66 Bn - 30.30 Mn
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn 14.75 Bn
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn 22.66 Bn
8 Evaxion A 65.12 Bn 65.10 Bn - -
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn 910.24 Mn
10 Mineralys Therapeutics 2.50 Bn 2.50 Bn - 392,000.00

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 392,000.00
Dec 31, 2025 420,000.00
Sep 30, 2025 151,000.00
Jun 30, 2025 455,000.00
Mar 31, 2025 435,000.00
Dec 31, 2024 552,000.00
Sep 30, 2024 521,000.00
Jun 30, 2024 491,000.00
Mar 31, 2024 430,000.00
Dec 31, 2023 2.53 Mn
Sep 30, 2023 12.18 Mn
Jun 30, 2023 21.73 Mn
Mar 31, 2023 31.16 Mn
Dec 31, 2022 1.63 Mn